PHAXIAM Therapeutics【PHXM】銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

0.684

買値

0.682

売値

0.716

出来高

21,804

0.662 日の範囲 0.722

0.1602 52 週間の範囲 3.08

時価総額

21.197M

前日終値

0.71

始値

0.71

時刻

122

0.684

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

37,156

発行済株式数

30,989,584

配当利回り

PER

-0.90

1 株当たり利益 (EPS)

-0.76

歳入

1.33M

純利益

-23.49M

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.phaxiam.com

本社

Lyon, Rhone, Fra

設立

PHAXIAM Therapeutics SA is listed in the Pharmaceutical Preparations sector of the ユーロネクスト with ticker PHXM. The last closing price for PHAXIAM Therapeutics was 0.71 €. Over the last year, PHAXIAM Therapeutics shares have traded in a share price range of 0.1602 € to 3.08 €.

PHAXIAM Therapeutics currently has 30,989,584 shares in issue. The market capitalisation of PHAXIAM Therapeutics is 22.00 € million. PHAXIAM Therapeutics has a price to earnings ratio (PE ratio) of -0.90.

PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy

Strategy built around two complementary development axes: GMP Individualized Phage Therapies (IPT) and Phage Therapies Medicinal Products...

PHAXIAM Therapeutics and Technophage Enter Strategic Collaboration On Individualized GMP Phages Therapies (IPT) Against Bacteria Responsible For ~ 70%(1) Of The Most Common Severe Resistant Infections

Combined 25 GMP(2) Phages Portfolio to cover by end 2025 five of the most critical pathogens (S. aureus, P. aeruginosa, E. coli, K. pneumoniae...

PHAXIAM Therapeutics Announces Its Financial Calendar for 2025

Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM – FR0011471135), a biopharmaceutical company developing innovative treatments for severe...

PHAXIAM Therapeutics Announces Updated Real-Life Clinical Data From Patients Treated Under the Compassionate Status in Europe

Promising clinical results observed in the first 88 patients evaluated so far, confirming the safety and an important clinical benefit for...

PHAXIAM : Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 décembre 2024

Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Regulatory News: PHAXIAM (Paris:PHXM) : Place de cotation : Euronext...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.066	-8.8	0.75	0.8	0.662	23079	0.6981113	DE
4	-0.616	-47.3846153846	1.3	1.344	0.53	71300	0.80362393	DE
12	-1.104	-61.744966443	1.788	1.94	0.1602	37156	1.03159476	DE
26	-1.066	-60.9142857143	1.75	2.145	0.1602	24305	1.2590799	DE
52	-2.256	-76.7346938776	2.94	3.08	0.1602	15658	1.48458459	DE
156	-0.106	-13.417721519	0.79	6	0.1602	26378	1.17168942	DE
260	-0.106	-13.417721519	0.79	6	0.1602	26378	1.17168942	DE

PHXM - Frequently Asked Questions (FAQ)

What is the current PHAXIAM Therapeutics share price?

The current share price of PHAXIAM Therapeutics is 0.684 €

How many PHAXIAM Therapeutics shares are in issue?

PHAXIAM Therapeutics has 30,989,584 shares in issue

What is the market cap of PHAXIAM Therapeutics?

The market capitalisation of PHAXIAM Therapeutics is EUR 22M

What is the 1 year trading range for PHAXIAM Therapeutics share price?

PHAXIAM Therapeutics has traded in the range of 0.1602 € to 3.08 € during the past year

What is the PE ratio of PHAXIAM Therapeutics?

The price to earnings ratio of PHAXIAM Therapeutics is -0.9

What is the cash to sales ratio of PHAXIAM Therapeutics?

The cash to sales ratio of PHAXIAM Therapeutics is 15.89

What is the reporting currency for PHAXIAM Therapeutics?

PHAXIAM Therapeutics reports financial results in EUR

What is the latest annual turnover for PHAXIAM Therapeutics?

The latest annual turnover of PHAXIAM Therapeutics is EUR 1.33M

What is the latest annual profit for PHAXIAM Therapeutics?

The latest annual profit of PHAXIAM Therapeutics is EUR -23.49M

What is the registered address of PHAXIAM Therapeutics?

The registered address for PHAXIAM Therapeutics is 60 AVENUE ROCKEFELLER, LYON, RHONE, 69008

What is the PHAXIAM Therapeutics website address?

The website address for PHAXIAM Therapeutics is www.phaxiam.com

Which industry sector does PHAXIAM Therapeutics operate in?

PHAXIAM Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

銘柄コード	株価	出来高
ALOPMOncodesign Precision Medicine SA	0.758 € (53.13%)	90.4k
LHYFELhyfe SA	4.10 € (29.95%)	158.39k
ALCABCabasse SA	0.52 € (27.14%)	37.01k
ALVGVEOM Group	0.23 € (18.62%)	93.08k
PLXPluxee NV	21.98 € (18.11%)	269.8k
DMSBSDiagnostic Medical Systems	0.0035 € (-30.00%)	30.63k
ALSENSensorion	0.17 € (-26.09%)	1.49M
POXELPoxel	0.381 € (-22.56%)	2.06M
ALALOAcheterLouerFR	0.0004 € (-20.00%)	109.87M
ALQWAQwamplify Activation	1.95 € (-18.73%)	280
ATOAtos SE	0.0036 € (-7.69%)	596.11M
ALALOAcheterLouerFR	0.0004 € (-20.00%)	109.87M
ALHPIHopium SA	0.0011 € (-8.33%)	100.39M
ALVERVergnet	0.0006 € (0.00%)	68.52M
BCPBanco Comercial Portugues SA	0.5358 € (-1.90%)	66.58M

銘柄コード

株価

出来高

ATOAtos SE

0.0036 €

(-7.69%)

596.11M

ALALOAcheterLouerFR

0.0004 €

(-20.00%)

109.87M

ALHPIHopium SA

0.0011 €

(-8.33%)

100.39M

ALVERVergnet

0.0006 €

(0.00%)

68.52M

BCPBanco Comercial Portugues SA

0.5358 €

(-1.90%)

66.58M

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

PHAXIAM Therapeutics SA (PHXM)

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

PHAXIAM Therapeutics SA について

PHXM 最新ニュース

PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy

PHAXIAM Therapeutics and Technophage Enter Strategic Collaboration On Individualized GMP Phages Therapies (IPT) Against Bacteria Responsible For ~ 70%(1) Of The Most Common Severe Resistant Infections

PHAXIAM Therapeutics Announces Its Financial Calendar for 2025

PHAXIAM Therapeutics Announces Updated Real-Life Clinical Data From Patients Treated Under the Compassionate Status in Europe

PHAXIAM : Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 décembre 2024

PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy

PHAXIAM Therapeutics et Technophage entament une collaboration stratégique portant sur les thérapies individualisées à base de phages (IPT) ciblant les bactéries responsables d’environ 70%(1) des infections résistantes sévères les plus répandues

PHAXIAM Therapeutics annonce son calendrier financier 2025

PHAXIAM Therapeutics annonce des données cliniques actualisées issues de patients traités sous statut compassionnel en Europe

PHAXIAM : Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 décembre 2024

PHAXIAM Therapeutics Presents Clinical Data of the PhagoDAIR Pilot Study, With Results Confirming the Design of the GLORIA Phase II Clinical Study

PHAXIAM Therapeutics : monthly information related to total number of voting rights and shares composing the share capital – November 29, 2024

PHAXIAM Therapeutics : information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 novembre 2024

PHXM - Frequently Asked Questions (FAQ)

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

PHAXIAM Therapeutics SA (PHXM) 銘柄情報

PHAXIAM Therapeutics SA (PHXM)

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

主要統計と詳細

PHAXIAM Therapeutics SA について

PHXM 最新ニュース

PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy

PHAXIAM Therapeutics and Technophage Enter Strategic Collaboration On Individualized GMP Phages Therapies (IPT) Against Bacteria Responsible For ~ 70%(1) Of The Most Common Severe Resistant Infections

PHAXIAM Therapeutics Announces Its Financial Calendar for 2025

PHAXIAM Therapeutics Announces Updated Real-Life Clinical Data From Patients Treated Under the Compassionate Status in Europe

PHAXIAM : Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 décembre 2024

PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy

PHAXIAM Therapeutics et Technophage entament une collaboration stratégique portant sur les thérapies individualisées à base de phages (IPT) ciblant les bactéries responsables d’environ 70%(1) des infections résistantes sévères les plus répandues

PHAXIAM Therapeutics annonce son calendrier financier 2025

PHAXIAM Therapeutics annonce des données cliniques actualisées issues de patients traités sous statut compassionnel en Europe

PHAXIAM : Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 décembre 2024

PHAXIAM Therapeutics Presents Clinical Data of the PhagoDAIR Pilot Study, With Results Confirming the Design of the GLORIA Phase II Clinical Study

PHAXIAM Therapeutics : monthly information related to total number of voting rights and shares composing the share capital – November 29, 2024

PHAXIAM Therapeutics : information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 novembre 2024

PHXM - Frequently Asked Questions (FAQ)

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

広告を削除する